M&A A Major Pillar Of Sumitomo Dainippon's New Mid-Term Plan
Executive Summary
Mid-size Japanese player Sumitomo Dainippon sets aside billions for potential M&A deals under a new business plan designed to fill gaps in its neurology pipeline as it prepares to lose exclusivity for its top global product.
You may also be interested in...
Napabucasin Failure Costly, And Possibly Transformative, For Dainippon
Japanese firm’s recent decision to halt development of its lead oncology asset, gained through a multi-billion-dollar acquisition where it was the main attraction, not only has a financial cost but may prompt more strategic deal-making.
Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe
Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.